Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN60340 + Azacitidine + Venetoclax in Newly Diagnosed AML
NCT07623187Phase 3Not yet recruiting
- Sponsor
- Ipsen
- Start
- Nov 2026
- Primary completion
- May 2031
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing IPN60340 in combination azacitidine plus venetoclax (IAV) with Placebo in combination azacitidine plus venetoclax (PAV) (2 arms). Primary endpoint: Complete Remission at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Ichnocim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07623187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623187.